
Key considerations for the CMC research of antibody-drug conjugates during the investigational new drug stage
Key considerations for the CMC research of antibody-drug conjugates during the investigational new drug stage
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 |
|
〉 |